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Abstract
Background: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of
heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and
validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3
(MRP3).
Methods: We investigated MRP3 by genetic and immunohistochemical (IHC) analysis of human gliomas to
determine the incidence, distribution, and localization of MRP3 antigens in GBM and their potential correlation with
survival. To determine MRP3 mRNA transcript and protein expression levels, we performed quantitative RT-PCR,
raising MRP3-specific antibodies, and IHC analysis with biopsies of newly diagnosed GBM patients. We used
univariate and multivariate analyses to assess the correlation of RNA expression and IHC of MRP3 with patient
survival, with and without adjustment for age, extent of resection, and KPS.
Results: Real-time PCR results from 67 GBM biopsies indicated that 59/67 (88%) samples highly expressed MRP3
mRNA transcripts, in contrast with minimal expression in normal brain samples. Rabbit polyvalent and murine
monoclonal antibodies generated against an extracellular span of MRP3 protein demonstrated reactivity with
defined MRP3-expressing cell lines and GBM patient biopsies by Western blotting and FACS analyses, the latter
establishing cell surface MRP3 protein expression. IHC evaluation of 46 GBM biopsy samples with anti-MRP3 IgG
revealed MRP3 in a primarily membranous and cytoplasmic pattern in 42 (91%) of the 46 samples. Relative RNA
expression was a strong predictor of survival for newly diagnosed GBM patients. Hazard of death for GBM patients
with high levels of MRP3 RNA expression was 2.71 (95% CI: 1.54-4.80) times that of patients with low/moderate
levels (p = 0.002).
Conclusions: Human GBMs overexpress MRP3 at both mRNA and protein levels, and elevated MRP3 mRNA levels
in GBM biopsy samples correlated with a higher risk of death. These data suggest that the tumor-associated
antigen MRP3 has potential use for prognosis and as a target for malignant glioma immunotherapy.
Background
Glioblastoma multiforme (GBM) is the most common
and aggressive neuroectodermal neoplasm in adults.
Although a recent study showed meaningful survival
benefit associated with chemotherapy using a temozolo-
mide-based chemoradiation approach [1], the median
progression-free survival among patients treated with
this regimen was only 7.9 months, and the overall
survival was only 14.6 months [1]. Thus, an effective
treatment for GBM patients is still a critical need.
Tumor-specific antigens that can be targeted by
monoclonal antibodies (MAbs) conjugated with either
radioisotopes or cytotoxins have great potential for can-
cer therapy [2,3]. MAbs have been applied to the treat-
ment of malignant gliomas through selective destruction
of tumor cells and sparing of normal brain cells [4,5].
Glioma-associated antigens targeted by immunothera-
peutic approaches include cell adhesion molecules,
matrix proteins, and growth factor receptors, such as
tenascin [6], wild-type epidermal growth factor receptor
[7], its glioma-associated variant, epidermal growth
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withstanding the tumor-restricted presentation of these
antigens, GBMs are a heterogeneous group of tumors,
consisting of genotypically and phenotypically divergent
populations of cells [10,11]. As a result, antigenic
expression profiles show a significant level of variation
among and within individual GBMs [12]. Antigenic
drift, observed in cultured cells, suggests the possibility
of antigenic escape in primary brain tumors during
treatment. Thus in any immunotherapeutic regimen, the
antigenic heterogeneity seen in GBM necessitates the
precise and timely selection of one or more target mole-
cules for each patient. One approach to circumvent neo-
plastic cell heterogeneity is to expand the spectrum of
GBM-specific targetable molecules and to customize
t h e r a p yb yu s i n gt h eb e s tc o m b i n a t i o no ft a r g e t e d
tumor antigens. Recent advances in genome technology
have made it possible to analyze systematically the dif-
ferences in gene expression patterns between normal
and cancer cells, providing opportunities to discover
novel antigens with tumor-specific distribution [13,14].
Multidrug-resistance protein 3 (MRP3), also known as
the ATP-binding cassette (ABC) superfamily C Member
3, or ABCC3, is an organic anion transporter that we
have recently identified as a candidate GBM marker by
t h es e r i a la n a l y s i so fg e n ee x p r e s s i o n( S A G E )m e t h o d
[15]. The best-studied mechanisms of multidrug resis-
tance in malignant cells involve the overexpression of
ATP-driven anticancer drug efflux pumps of the ABC
superfamily [16]. MRP3 is involved in ATP-dependent
transport of hydrophobic compounds [17] and of bile
acids under certain physiological conditions [18]. MRP3
has limited distribution in human normal tissues and is
expressed in adrenal gland, kidney, placenta, and organs
of the gastrointestinal tract, including intestine, pan-
creas, liver, and gallbladder [19,20]. Recent work using
MRP3-transfected cell lines has demonstrated the ability
of MRP3 to transport certain classes of cytotoxic antic-
ancer agents [21-23]. Accumulating evidence indicates
that MRP3 gene expression is ectopically activated dur-
ing carcinogenesis. MRP3,a sm R N Ao rp r o t e i n ,h a s
been detected in a variety of human cancer cell lines
and tissues, including malignant gliomas [24-30], which
implies possible involvement of MRP3 in the acquisition
of a drug-resistant phenotype in these tumors.
Calatozzolo et al. showed that, in contrast to expression
levels in nontumor brain samples, normal human astro-
cytes, and cultured endothelial cells, MRP3 is hyperex-
pressed in astrocytomas as the primary resistance to
chemotherapy with drugs like cis-platinum (CDDP) and
carmustine (BCNU) [31] and that MRP3 can modulate
drug sensitivity to certain anticancer agents, such as cispla-
tin, vincristine, and etoposide, in human gliomas [25]. It
has recently been shown that hepatic progenitor cells have
high expression levels of functional MRP1 and MRP3,
which may have a role in removing either exogenous or
endogenous toxins and metabolites from progenitor cells
[32]. Expression of ABC transporters was also found to be
responsible for the highly enriched population phenotype
in a wide variety of stem cells [33], and other initial studies
also showed that they may be active in hematopoietic stem
cells as functional regulators [34]. Although MRP3 was
much less expressed in cancer stem cells before differen-
tiation, after differentiation, the expression of MRP3 nota-
bly rose, which suggests that just after differentiation the
cells acquired chemotherapeutic resistance via MRP3 [35].
In our preliminary survey of a limited number of
glioma samples, MRP3 mRNA transcripts were highly
expressed (80- to 100-fold induction) in comparison
with normal brain tissues [15]. MRP3 could be an
important target for immunotherapy, if the expression
of MRP3 RNA by gliomas and minimum of expression
in normal brain is reflective of actual MRP3 protein
expression. This, along with its transmembrane localiza-
tion, makes MRP3 an attractive target in immunother-
apy for malignant gliomas. More pertinent, MRP3 is a
tumor rejection antigen recognized by cytotoxic T lym-
phocytes in human lung adenocarcinomas [36]. How-
ever, little is known about MRP3 mRNA and protein
expression in a large number of newly diagnosed GBM
patient samples. We have therefore proposed to investi-
gate the suitability of this MRP3 marker as a glioma
immunotherapeutic target.
In this study, we conducted a genetic and immunohis-
tochemical (IHC) evaluation of human gliomas to deter-
mine the incidence, distribution, and pattern of
localization of MRP3 antigens in brain tumors. To
assess the therapeutic potential of MRP3 as a GBM-
associated antigen, we used real-time reverse transcrip-
tion-polymerase chain reaction (RT-PCR) to determine
MRP3 RNA transcript levels in 67 biopsy specimens
from newly diagnosed GBM patients. In addition, a
panel of 46 newly diagnosed GBM cases was assessed
for MRP3 protein expression by IHC analysis, and survi-
val analyses were performed based on these two para-
meters. We provide evidence that MRP3 mRNA
expression is up-regulated in the majority of GBM cases
and that glioma cells express MRP3 protein in vitro and
in vivo. Increased MRP3 mRNA expression in GBM
biopsy samples correlated with a higher risk of death.
We demonstrate that MRP3 is a good potential molecu-
lar target for the immunotherapeutic treatment of
malignant gliomas.
Methods
Cell lines
Human GBM-derived cell lines D54 MG, D247 MG,
D392 MG, and D245 MG were established and
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Page 2 of 15maintained in our laboratory [10]; T98G and U251 MG
were obtained from the ATCC. Glioma cells were
g r o w ni nZ i n cO p t i o nm e d i u ms u p p l e m e n t e dw i t h1 0 %
FCS (ZO-10% FCS). Cell lines with defined expression
of MRP molecules were the kind gift of Dr. Piet Borst
[21,37,38]. This defined cell line system consists of the
nontransfected parent cell line 2008 (human ovarian
carcinoma) transfected to express MRP1, MRP2, or
MRP3. The HEK293 (human embryonic kidney) cell
line was transfected to express MRP4. The MCDK
(canine kidney) cell line was transfected to express
MRP5. The monospecificity of MRP expression by this
panel has been established [38]; all cell lines were grown
in 10% FCS-DMEM (GIBCO/BRL 15050-022 [Invitrogen
Corp., Carlsbad, CA]; with high glucose and phenol red)
and split with 0.05% trypsin/EDTA.
For transient and stable expression, the cDNA of
MRP3 was ligated into the mammalian expression vec-
tor pcDNA3.1 (Invitrogen, Carlsbad, CA). The resulting
pcDNA3.1-MRP3 was introduced into HEK293 cells by
using the Lipofectamine 2000 reagent (Invitrogen), and
transiently transfected cells were harvested 48 h later.
Stably transfected clones were selected in medium con-
taining 200 μg/ml of Zeocin (Invitrogen).
Brain tumor samples
Samples of primary GBM (Grade IV, according to WHO
criteria [39]) tumors were obtained from 94 newly diag-
nosed patients at the Department of Neurosurgery,
Duke University Medical Center. Among those 94 GBM
samples, as summarized for the patient characteristics in
Table 1, 67 cases were evaluated by quantitative RT-
PCR analysis for MRP3 mRNA transcript expression
and 46 cases were evaluated by IHC analysis for MRP3
protein expression. No patient had any history of che-
motherapy or radiotherapy before surgery. The samples
were immediately snap-frozen in liquid nitrogen and
stored at -80°C until analysis.
Quantitative RT-PCR assay
Total cellular RNA for use in the quantitative RT-PCR
assay was isolated from confluent cultured cells and
tumor tissues by using an RNeasy Mini Kit (Qiagen,
Valencia, CA) and then treated with RNase-free DNase I
(Ambion, Austin, TX). Total RNA of normal adult
whole brain was either purchased from Clontech (Palo
Alto, CA) or obtained from the Brain Tumor BioReposi-
tory, Preston Robert Tisch Brain Tumor Center, Duke
University Medical Center. These total RNA samples
(0.2 μg) were converted to random-primed cDNA with
SuperScript II RNaseH
- Reverse Transcriptase (Life
Technologies, Rockville, MD) in a reaction volume of 20
μl. After reverse transcription, 280 μl of water was
added to the reaction mixture, and 2 μlo fd i l u t e d
cDNA sample was used as a template in PCR
experiments.
The synthesized first-strand cDNA samples were sub-
jected to real-time PCR with SYBR Green dye. Incor-
poration of SYBR Green dye into the PCR products was
monitored with an ABI PRISM 7900HT Sequence
Detector System (Applied Biosystems, Foster City, CA).
For PCR reactions, 2 μlo fc D N A ,5μlo f2 ×S Y B R
Green PCR Master Mix (Applied Biosystems, Warring-
ton, UK), and 200 nM of each primer were used in a
total volume of 10 μl. Cycling parameters were 50°C for
2 min and 95°C for 10 min, followed by 40 cycles of 95°
C for 15 s and 64°C for 30 s. For each sample, b-actin
transcript was amplified simultaneously as an internal
control. To avoid amplification from contaminating
genomic DNA, primer pairs were designed to amplify
sequences spanning introns. The oligonucleotide primer
sequences were as follows.
MRP3 (sense) 5′-TGCCATCGACCTGGAGACTGA-
CAAC-3′
MRP3 (antisense) 5′-GACATATTTGGTGTCA
TTTCCTTCCTGATG-3′
b-actin (sense) 5′-CCAACCGCGAGAAGATGACC-
CAGATCATGT-3′
b-actin (antisense) 5′-GGTGAGGATCTTCAT-
GAGGTAGTCAGTCAGG-3′
The integrity of PCR products was confirmed by dis-
sociation curve analysis using SDS 2.0 software (Applied
Biosystems) and agarose gel electrophoresis followed by
ethidium bromide staining. The threshold cycle (CT)
values were determined for MRP3 and corresponding b-
actin genes. To normalize the amount and quality of
total RNA used in cDNA synthesis, the MRP3/b-actin
ratio was calculated from the following formula for each
sample:
MRP actin
actin MRP 3
3 /
() 
 −=
−−  ratio 2
CC T T
In each tumor, relative MRP3 mRNA expression levels
were measured in terms of fold induction ratio over
normal whole-brain sample, which was determined by
dividing the MRP3/b-actin ratio of the tumor sample by
that of control normal whole brain. All measurements
were performed in triplicate wells and repeated twice.
Positive cases were defined as those with MRP3 RNA
levels 3-fold higher than normal brain.
MRP3 fusion protein
To obtain antibodies reactive with the extracellular epi-
topes of MRP3, a fusion protein consisting of the
Escherichia coli maltose-binding protein (MBP) and one
of the membrane-associated regions (MARs) of MRP3
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England BioLab, Beverly, MA). The MRP3 sequence in
the expression vector encoded a 241-amino acid frag-
ment (aa 984 to 1224) of MRP3 and was designated as
MAR3 (Fig. 1A). The boundaries of MRP3 domains
were determined according to the membrane topology
model for MRP1 [40]. The DNA fragment encoding the
MAR3 domain of MRP3 was PCR amplified from the
plasmid vector pGEM7Zf-MRP3 containing full-length
MRP3 cDNA (kindly provided by Dr. Marcel de Haas,
The Netherlands Cancer Institute, Amsterdam) with the
following primers.
sense: 5′-TCGGATCCGGCACCATGGCTGCCA
TTGGAGCCAATGTG-3′
antisense: 5′-AGTCTAGATTACCCCGGGTTCAG
GCTGCTCCT-3′
After digestion with BamHI and XbaI, the MAR3
DNA fragment was cloned into the corresponding
Table 1 Patient Characteristics
Patient characteristic All patients Patients with MRP3 IHC Data Patients with MRP3 mRNA Data
# of Patients 94 46 67
Gender:
Male 59 (63%) 30 (65%) 39 (42%)
Female 35 (37%) 16 (35%) 28 (59%)
Age:
≤ 45 years 22 (23%) 10 (22%) 13 (19%)
>45 years 72 (77%) 36 (78%) 54 (81%)
KPS:
90-100 51 (54%) 23 (50%) 38 (57%)
70 - 80 36 (38%) 21 (46%) 24 (36%)
50 - 60 5 (5%) 2 (4%) 3 (4%)
Unknown 2 (2%) 0 2 (3%)
Extent of Resection:
GTR 75 (80%) 34 (74%) 55 (82%)
STR 17 (18%) 10 (22%) 12 (18%)
Biopsy 2 (2%) 2 (4%) 0
Post-operative Treatment:
CPT-11 2 (2%) 2 (4%) 1 (1%)
CPT-11/Celebrex 2 (2%) 2 (4%) 0
Cyclophosphamide/Thalidomide 1 (1%) 1 (2%) 0
Gliadel 4 (4%) 2 (4%) 2 (3%)
Gliadel®XRT 7 (7%) 5 (11%) 7 (10%)
Gliadel®XRT/Temo 4 (4%) 2 (4%) 2 (3%)
Mab I
131-81C6 8 (9%) 5 (11%) 7 (10%)
Temozolomide 3 (3%) 2 (4%) 2 (3%)
Temozolomide/CPT-11 1 (1%) 0 1 (1%)
Temozolomide/Avastin 1 (1%) 0 1 (1%)
Vincristine/Cisplatin/Cyclophosphamide 1 (1%) 1 (2%) 0
XRT 19 (20%) 12 (26%) 15 (22%)
XRT/Temo 37 (39%) 11 (24%) 26 (39%)
None/Unknown 4 (4%) 1 (2%) 3 (4%)
Survival Status:
Alive 7 (7%) 3 (7%) 5 (7%)
Dead 87 (93%) 43 (93%) 62 (93%)
Available Data:
RNA only 48 (51%) 0 48 (72%)
IHC only 27 (29%) 27 (59%) 0
RNA and IHC 19 (20%) 19 (41%) 19 (28%)
Abbreviations: IHC: immunohistochemical, GTR: Gross Total Resection, STR: Subtotal Resection, XRT: External Beam Radiation Therapy.
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the MAR3 domain was also amplified by RT-PCR by
using the same PCR primers and total RNA isolated
from human glioma cell line T98G as a template. DNA
sequencing revealed that nucleotide sequence of the
MAR3 segment of MRP3 expressed in T98G was the
same as that in pGEM7Zf-MRP3 and in previous reports
[21,41] (data not shown). The resulting fusion protein
MAR3-MBP was produced in E. coli TG1 and purified
from cytosol medium with amylose resin affinity chro-
matography according to the manufacturer’s
instructions.
Immunization
Rabbits were given a primary s.c. immunization with
250 μg of recombinant protein MAR3-MBP emulsified
1:1 in Freund’s complete adjuvant and were subse-
quently boosted with the same dose of antigen emulsi-
fied 1:1 in Freund’s incomplete adjuvant at 4-week
intervals. Serum titers were determined by ELISA versus
MAR3-MBP or MBP alone as target antigens and by
live-cell-ELISA using MRP3-expressing D247 MG cells
as targets [8]. Sera obtained 12 days following the sixth
immunization were passed over a staphylococcal protein
A column as previously described [42], and the rabbit
immunoglobulin concentration was determined by cap-
ture ELISA [42].
Balb/c mice (NCI Animal Production Program, Freder-
ick, MD) were similarly immunized with protein MAR3-
MBP on days 171 and 191, following a four-dose immuni-
zation regimen with pcDNA3.1-MAR3 over days 1–87;
the DNA-alone immunization protocol failed to produce
titers sufficient to warrant fusion. Following MAR3-MBP
protein boosts, 50% endpoint titers to target were in
excess of 1/10,000, and spleens of two mice were fused.
MAbs were initially identified for positivity with MAR3-
MBP and absence of reactivity with MBP by ELISA; subse-
quently, they were further screened on cell lines that were
determined, by mRNA analysis and reactivity with the
polyvalent rabbit anti-MAR3-MBP serum, to be MRP3
positive (Western blot and indirect immunofluorescence
analysis). Anti-MAR3 MAb 16A11, of the IgG2a isotype,
was chosen because of its superior reactivity in indirect
FACS analysis with MRP3-expressing D54 MG cells.
Western blotting
Cells were lysed in NP-40 lysis buffer (50 mM Tris-Cl,
pH 8.0/150 mM NaCl/1% NP-40/1 mM phenylmethyl-
sulfonyl fluoride/0.045 mg/ml aprotinin). Aliquots of
10 μg of total protein were separated by SDS-PAGE and
Figure 1 Structure of MRP3 and expression of MRP3 mRNA in glioblastoma-derived cell lines. (A) MRP3 structure. Upper: the organization
of MRP3. Lower: membrane topology model for MRP3 (modified from Hipfner et al. [40]). MAR1, MAR2, MAR3, membrane-associated regions 1-3;
L1, L2, linker domains 1 and 2; NBD1, NBD2, nucleotide-binding domains 1 and 2. Positions of PCR primers are indicated by arrows. (B) RT-PCR
results showing MRP3 mRNA expression (Upper) and b-actin expression (Lower) in GBM cell lines U251 MG, T98G, D245 MG, D54 MG, D247 MG,
and D392 MG.
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Membranes were incubated with 3% non-fat milk in
PBS-0.1% Tween 20 to block nonspecific binding and
were then probed overnight at 4°C with rabbit
anti-MAR3 antiserum 1708 in PBS-0.1% Tween 20 con-
taining 1% milk. The protein bands were detected by
horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG secondary antibody coupled with SuperSignal West
Pico Chemiluminescence Kit (Pierce, Rockford, IL).
Indirect FACS analysis
Flow cytometric analysis for MRP3 expression was per-
formed as described previously [43]. Test reagents and
wash buffers were kept on ice to ensure the detection of
cell surface molecules without allowing internalization
to occur. Target cells were detached from culture flasks
by incubation with 0.02% EDTA/PBS. Then, 1 × 10
6
cells/reaction mixture were maintained in 0.5% parafor-
maldehyde/PBS for 10 min at 4°C, washed, resuspended
in 150 μl of PBS containing 10% FBS, and blocked for
20 min at 4°C. After two washes, the samples were
reacted with rabbit anti-MAR3 1708 purified IgG, nor-
mal rabbit IgG, MAb 16A11, or murine IgG2a (all at 10
μg/ml in PBS) and rotated for 1 h at 4°C. After two
additional washes, cells were incubated with species-
appropriate FITC-labeled secondary antibody for 30 min
at 4°C and then analyzed on a Becton Dickinson FAC-
Sort flow cytometer and cell sorter system (Becton
Dickinson, San Jose, CA).
Quantitative FACS analysis
We have previously published our techniques for
QFACS analysis in the EGFRvIII MAb-antigen system
[43]; briefly, FITC-MAb 16A11 is reacted with a cocktail
of beads (Bangs Laboratories, Inc., Fishers IN) which
bind no (B1) or graded amounts (20,000-200,000 [B2-
B5]) of murine IgG molecules. Regression analysis of
bead-binding capacity versus FL1 height is performed,
generating a straight line formula, from which we calcu-
late the number of molecules of FITC-MAb 16A11
bound to the target cells of identical aliquots, assuming
1:1 stoichiometry.
Anti-MRP antibodies
All anti-MRP reagents were obtained from Kamiya Bio-
medical Company (Seattle, WA). Anti-MRP1 (MRPm6,
IgG1), anti-MRP-2 (M2II-12, IgG2a), and anti-MRP3
(M3II-9; IgG1) are all murine monoclonal reagents direc-
ted against the cytoplasmic domain epitopes of their
respective targets. Anti-MRP4 (M4I-10) and anti-MRP5
(M5I-1), from the same source, are rat IgG2a MAbs, also
directed against a cytoplasmic domain epitope.
Analysis of cells grown on chambered slides
Target cells were plated at densities determined in pre-
vious assays to yield a 70-80% confluent monolayer in
either 24 or 48 h. Our IHC procedure using Lab-Tek
Chamber Slides (Electron Microscopy Sciences, Hatfield,
PA) has been published previously [43]; however Triton X
treatment was omitted, as detection of nuclear staining
was not an objective. Due to the cytoplasmic location of
the epitopes detected by commercial reagents, all assays
were performed in the presence of saponin, to allow pene-
tration of reagents to the cytoplasm. Following fixation,
blocking, and permeabilization, primary reagents (all at
12.5 μg/ml) were applied, and the assay continued as
described, with the exception that the secondary reagent
used was biotinylated horse anti-mouse IgG (Zymed, San
Francisco, CA) or biotinylated goat anti-rat IgG (Caltag) as
appropriate. Slides were counterstained with hematoxylin
and read by two independent observers.
Immunohistochemistry
Immunohistochemical staining of frozen sections derived
from human glioma tumors was performed as described
previously [43] using rabbit polyvalent anti-MAR3 anti-
serum 1708 purified IgG. Briefly, frozen tissues were sec-
tioned (5-7 mm), mounted on positively charged slides,
air-dried for 30 min, and fixed in cold acetone for 30 s.
Nonspecific protein binding sites were blocked at room
temperature with PBS containing 10% normal goat
serum for 30 min, followed by incubation with primary
antibodies at 10 μg/ml for 2 h. Positive reactions were
detected by using biotinylated goat anti-rabbit IgG and
HRP-conjugated streptavidin (Zymed). Bound peroxidase
was developed with diaminobenzidine for 5 min. As a
negative primary reagent control, irrelevant normal rab-
bit immunoglobulin (10 μg/ml) was used.
Slides were counterstained with hematoxylin, dehy-
drated, mounted, coded, and read by two investigators;
staining patterns were scored as focal, multifocal, or dif-
fuse, both in perivascular and parenchymal distribution,
with intensity of stain described as weak, moderate, or
strong.
Statistical analyses
Cox’s proportional hazards model was used to examine
the effect of MRP3 mRNA expression (≤10-fold vs >10-
fold) and IHC (zero vs positive) on survival, which was
computed from the date of pathology sample acquisition
to date of death or last contact. Patient characteristics
such as gender, age, KPS, extent of resection, histology,
post-operative treatment, and survival status are shown
in Table 1. Analyses were conducted with and without
adjustment for known prognostic factors such as age
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vs STR/biopsy), and KPS (90-100 vs <90). Backwards
elimination was used to identify a parsimonious multi-
variable model (SAS statistical analysis package, Cary,
NC).
Results
Quantification of MRP3 mRNA in glioblastoma-derived
cell lines and GBM samples
We first assessed MRP3 mRNA expression levels in
human GBM cell lines. All six GBM-derived cell lines
examined expressed MRP3 mRNA transcripts at differ-
ent levels (Fig. 1B and 1C). By quantitative RT-PCR,
T98G, D247 MG, and D54 MG cells exhibited relatively
high levels of MRP3 mRNA, ranging from 7.5- to 20-
fold induction ratios over normal brain, whereas D245
MG and U251 MG exhibited moderate levels, a 3-fold
induction ratio over normal brain, and the MRP3
mRNA level detected in D392 MG was similar to that
in normal brain (Fig. 2). One leukemia cell line, HL60,
w a su s e da san e g a t i v ec o n t r o l ,a n dn oR T - P C Rp r o -
ducts were detected (data not shown). Therefore, we
used T98G, D247 MG, and D54 MG cells in analyses
for MRP3 protein expression.
Incidence of MRP3 mRNA expression in GBM patient
samples
From the whole series of 94 newly diagnosed GBM
patients, we measured MRP3 mRNA levels in 67 GBM
biopsy samples. MRP3 mRNA expression was measured
by quantitative RT-PCR in tumor samples and com-
pared to that of normal whole brain (Fig. 2). Positive
cases were defined as those with MRP3 RNA levels 3-
fold higher than the level in normal brain. We found
that 59 (88%) of the 67 GBM samples were positive, the
MRP3 mRNA induction ranging from 3.5- to 370-fold
over that in normal brain. Significantly, 43 (64%) of the
67 cases had expression of MRP3 mRNA greater than
10-fold over that seen in normal brain RNA extracts
(data not shown). The expression levels of MRP3
Figure 2 Quantitative comparison of MRP3 mRNA levels in glioblastoma cell lines. After normalization to b-actin, which had minimal
variation in all normal and malignant samples that we tested, relative MRP3 mRNA transcript levels were expressed as compared to normal
whole brain (NWB), which was set equal to 1. Results are expressed as the mean ± SD of four independent real-time PCR experiments, including
a six-NWB sample average as the baseline standard. Inset: Incidence of MRP3 mRNA expression in GBM patient samples. Relative MRP3 mRNA
expression was measured by quantitative RT-PCR in GBM tumor samples (n = 67) over NWB (n = 6). Results are the mean of triplicate
measurements repeated twice. Positive cases were defined as those with MRP3 RNA levels 3-fold higher than normal brain; >10-fold: MRP3 RNA
levels >10-fold those of normal brain.
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level of gliomas (data not shown). Only minimal expres-
sion for the MRP3 gene was detected as a definable
baseline in normal brain samples assayed
simultaneously.
Detection of MRP3 protein in glioblastoma cells
By Western blotting with rabbit polyclonal anti-MAR3
antiserum 1708, purified MAR3-MBP protein was
detected as a 69-kDa protein band (Fig. 3A, lane 1). To
establish the restricted specificity of this rabbit antiserum,
Western blots were also performed using the HEK293
cells as a negative control (Fig. 3A, lane 2), the MRP3-
transfected HEK293 cells, and the T98G glioblastoma
cell line. MRP3 was detected in the MRP3-transfected
HEK293 cells as well as the MRP3-positive T98G cells as
an ~185-kDa protein (Fig. 3A, lanes 3 and 4), close to the
molecular mass of MRP3 reported previously [21,23,44].
In indirect flow cytometric analyses under conditions
measuring cell-surface-expressed targets, anti-MRP3
MAb 16A11 (Fig. 3B) and polyclonal antiserum 1708
reacted (data not shown) with MRP3-expressing T98G
MG cells, demonstrating the existence of MRP3 epitopes
on the cell surface membrane of live human GBM cells.
Quantitative FACS analysis of MRP3 expression by cell
lines, biopsies, and established xenografts with MAb
16A11
As described in Materials and Methods, MAb 16A11
was used to visualize the population profile of each sam-
ple, as well as to estimate the number of detected MRP3
molecules per cell surface, under conditions assuming
1:1 stoichiometry between antibody molecule and anti-
gen, an assumption verified by comparison to standard
Figure 3 Detection of MRP3 in a GBM cell line and in MRP3-transfected cells. (A) Western Blot. Lane 1, reactivity of purified IgG from rabbit
anti-MAR3 antiserum 1780 for fusion protein MAR3-MBP (~69 kD); lanes 2 and 3, protein extract (10 μg) of HEK293 cells transfected with the
parental pcDNA3.1 and with pcDNA3.1-MRP3 plasmid, respectively; lane 4, protein extracts (10 μg) of MRP3-positive T98G cells that were
electrophoresed and probed with rabbit anti-MAR3 antiserum 1708. The ~185-kDa mature MRP3 protein is indicated by an arrow. The locations of
protein molecular weight markers are shown to the left. (B) Indirect FACS analysis. Reactivity of MAb 16A11 for non-permeabilized MRP3-expressing
T98G cells, demonstration of a cell surface epitope. Irrelevant purified murine IgG2a was used as a negative control. (C) Quantitative FACS analysis of
purified, directly fluoresceinated MRP3-specific MAb 16A11 with established human glioma cell line D54 MG; median MRP3 antigen density/cell: 4.4
×1 0
4. (D) Quantitative FACS analysis of MAb 16A11 with human glioma biopsy sample TB 2155 MG; median MRP3 antigen density/cell: 2.7 × 10
4.
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system [8]. The results of QFACS analysis of human-
glioma-derived cell lines, biopsies, and xenografts are
summarized in Table 2.
We used FITC-MAb 16A11 with QFACS analysis to
i n v e s t i g a t eM R P 3d e n s i t yo nt h ec e l ls u r f a c eo ft h ec u l -
tured glioma cell lines shown to express MRP3 mRNA–
D54 MG, D247 MG, T98G, U251, and D392 MG–and
on human GBM biopsy samples. D54 MG cells were
relatively homogeneous in expression of MRP3 on the
cell surface (Fig. 3C), with a median density of 4.4 × 10
4
molecules per cell (6 repeat assays). D247 MG similarly
expressed a median density of 2.3 × 10
4 molecules per
cell, T98G expressed 0.38–4.9 × 10
5 molecules of MRP3
per cell (8 repeat assays; data not shown), U251 MG
cells exhibited 0.4–2.1 × 10
5 MRP3 molecules per cell
(3 repeat assays; data not shown), and D392 MG was
uniformly negative for cell surface expression of MRP3
(4 repeat assays; data not shown).
Biopsies and xenografts of GBM tended to express
lower cell surface MRP3 densities (median values in the
10
4 range) than did cell lines (median = 1.9 × 10
5). Of
six adult anaplastic astrocytoma (AA) biopsies analyzed
(single assay in triplicate on freshly isolated cells), three
were positive for cell surface MRP3, with a range in
expression of 1.7–2.7 × 10
4 MRP3 molecules per cell
(Table 2). Significantly, 22/27 adult GBM biopsies (82%)
were positive for cell surface MRP3, with a range in
expression of 0.17–6.5 × 10
5 ( m e d i a n=6 . 5×1 0
4)
MRP3 molecules per cell (Table 2). Representative data
from TB 2155 MG is shown in Fig. 3D (density/cell:
2.7 × 10
4); again, the density distribution by these
biopsy-derived cells is relatively homogeneous. This ten-
dency was also observed in the medulloblastoma cell
lines and xenografts examined. Of the six adult AA
biopsy samples that were available for analysis, only 50%
were positive, as opposed to 82% for GBM biopsies.
Unlike the EGFRvIII variant, MRP3 appears to be main-
tained over time in cell culture. The slightly lower fre-
quency of expression in established GBM xenografts
(57%) may be preliminary due to the small sample size
(7 cases).
Immunohistochemical analysis of defined cell lines
variously transfected to express MRP1-5
To validate the specificity of the polyvalent antiserum
1708 and MAb 16A11, we obtained the defined cell line
system reported previously [21,37,38], which consists of
the non-transfected parent cell line 2008 (human ovar-
ian carcinoma) transfected to express either MRP1,
MRP2, or MRP3, the HEK293 cell line transfected to
express MRP4, and the MCDK canine kidney cell line
transfected to express MRP5. The monospecificity of
MRP expression by this panel has been established [38].
Defined antisera to each of the MRP proteins were used
for comparison to the spectrum of reactivity exhibited
by the immune reagents reported here, polyvalent rabbit
antiserum 1708 and MAb 16A11. Untransfected parent
Table 2 Quantitative FACS analysis of MRP3 expression by biopsies, cell lines, and established xenografts with MAb
16A11
Diagnosis Positive cases/Total cases Percent Estimated number of MRP3 molecules per cell
Cell Lines
GBM adult 6/7 86 0.1-4.9 × 10
5 (med. = 1.9 × 10
5)
MED pediatric 5/5 100 0.7–2×1 0
5 (med. = 1 × 10
5)
Biopsies
AA adult 3/6 50 1.7–2.7 × 10
4
GBM adult 22/27 82 0.17–6.5 × 10
5 (med. = 6.5 × 10
4)
Xenografts
GBM adult 4/7 57 0.2–2.1 × 10
5
MED pediatric 2/3 67 1.6–2.5 × 10
4
Table 3 Immunohistochemical analysis of defined MRP-
expressing cell lines*
Antibody Parent MRP1-
tf
MRP2-
tf
MRP3-
tf
MRP4-
tf
MRP5-
tf
Negative
Control
000000
Anti-MRP1 0 2+ 0 0 0 0
Anti-MRP2 0 0 2+ 0 0 0
Anti-MRP3
(M3II-9)
0002 +00
Anti-MRP3
(16A11)
0002 +00
Anti-MRP3
(1708)
0002 +00
Anti-MRP4 0 0 0 0 2+ 0
Anti-MRP5 0 0 0 0 0 2+
*Parent, untransfected lines and their single MRP-transfected, derived lines
(-tf) were grown on Lab-Tek chambers for IHC analysis. Primary antibodies
and irrelevant controls were used at a concentration of 12.5 μg/ml (MAbs) or
10 μg/ml (polyvalent serum 1708 or normal rabbit IgG). Columns are headed
by the target cell line designation; rows are labeled to the left with the
primary antibody used for specific MRP detection. 0, 2+: levels of reactivity of
the antibodies with each defined MRP-expressing cell line.
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(Table 3, Parent column); shown here is the murine
IgG2a irrelevant primary antibody control; normal rabbit
IgG, controlled for concentrations of reference antisera,
was also negative. The results demonstrate the specifi-
city of the commercial reagents employed for their
respective targets, and the single, appropriate MRP
molecule expression by each of the transfectants
(MRP1-tf, MRP2-tf, MRP3-tf,M R P 4 - t f ,a n dM R P 5 - t f ) .
Most importantly, MAb 16A11 and polyvalent serum
1708 are identical in their reactivity profile to the com-
mercially available and consensus polyvalent antibody
control for MRP3 detection, M3II-9: These three
reagents detect only the MRP3-tf cell line.
Immunohistochemical analysis
We next investigated whether MRP3 proteins are
expressed in human malignant glioma tissues. As
described in Materials and Methods, polyvalent anti-
MRP3 antiserum 1708 was used to detect the presence of
MRP3 in frozen sections of GBM biopsy material. The
results of this analysis are reported in Table 4. Immunos-
taining with rabbit anti-MRP3 IgG in 46 cases of GBM
revealed MRP3, in a primarily membranous and cytoplas-
mic pattern, in 42 of the 46 GBM samples. Focal perivas-
cular enhanced localization was seen in 18 of the 46
GBM samples. Normal CNS histology was also done with
anti-MRP3 rabbit serum 1708 or MAbs such as 16A11,
and no IHC staining was observed (data not shown).
The majority of cases (40/46 GBMs [87%], Table 4)
exhibited prominent parenchymal staining (Fig. 4B and
4D), frequently coupled with multifocally enhanced peri-
vascular localization (Fig. 4B). Even when the localiza-
tion was focal in distribution, both cytoplasmic staining
and membrane staining were seen (Fig. 4D). Control
sections (Fig. 4A and 4C) probed with irrelevant normal
rabbit immunoglobulin showed no reactivity. In general,
the pattern of MRP3 immunoreactivity is predominantly
perivascular and involves small veins more commonly
than small arterioles. Tumor cell localization largely fol-
lows a perivascular enhancement (Fig. 4B). Rarely in
astrocytic tumors (AA [result not shown] and GBM) is
the entire biopsy sample reactive; the predominant
pattern is multifocal or focal, with groups of reactive
cells varying from weakly membranous to strongly
cytoplasmic, and membranous localization adjacent to
nonreactive cells (Fig. 4B and 4C). In contrast, oligoden-
drogliomas revealed a perinuclear-to-nuclear pattern in
a heterogeneous mixture of reactive and nonreactive
cells (result not shown).
Statistical analyses
The characteristics of the 94 patients included in these
analyses are summarized in Table 1, with a separate
characterization of patients with IHC and RNA data.
Overall, 87 of the 94 patients (93%) have died. The RNA
expression data is from 67 newly diagnosed GBM
patients and the IHC information from 46 newly diag-
nosed patients. We conducted survival analyses in a uni-
variate model to examine the effects on survival of
selected predictors such as age, KPS, extent of resection,
RNA level of MRP3, and anti-MRP3 IHC positivity in
specific patient subgroups and determined the hazard
ratio (HR) associated with each predictor. These univari-
ate analyses show the following: (1) Patients with a gross
total resection live longer than patients with less than a
gross resection (p = 0.0004; HR = 0.38 with 95% confi-
dence interval 0.22, 0.64). (2) The mRNA level of MRP3
is a strong predictor of survival, with statistical signifi-
cance (p = 0.002) in that patients with RNA levels less
than or equal to 10-fold over normal brain level were
predicted to live longer than patients with higher RNA
levels (p = 0.002; HR = 2.71 with 95% confidence inter-
val 1.54, 4.8), as shown in Fig. 5. However, (3) there was
no statistically significant relationship between IHC
reactivity and survival, and thus IHC positivity is not
predictive of survival (p = 0.466).
M u l t i v a r i a b l es u r v i v a lm o d e l sw e r ea l s or u nf o rs u r v i -
val analyses. Backwards elimination was used to gener-
ate these models while retaining either the IHC or the
mRNA predictor in the model. In these multivariable
analyses, IHC positivity is not predictive of survival (p =
0.723). However, after adjustment for extent of resec-
tion, high levels of RNA remain a significant predictor
of survival (p = 0.001; HR = 2.54 with 95% confidence
interval 1.44, 4.49).
Discussion
In an ideal situation, target antigens for passive immu-
notherapy should be (1) tumor specific, that is,
Table 4 Summary of immunohistochemical evaluation of
frozen GBM tissue sections with polyvalent anti-MRP3
antiserum 1708
Reactivity patterns GBM
Parenchymal
22/46
(48%)
Perivascular
2/46
(4%)
Parenchymal and perivascular
18/46
(39%)
Total reactive
42/46
(91%)
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Page 10 of 15Figure 4 Immunohistochemical analysis of frozen sections of human GBM with anti-MRP3 rabbit antiserum 1708. (A and B) GBM 2407;
(C and D) GBM 2362; all at 100×. (A and C) Normal rabbit IgG primary reagent control at an IgG concentration identical to that used for anti-
MAR3 antiserum 1708 (B and D). (B) GBM 2407 exhibits multifocal staining by antibody 1708, with enhanced perivascular localization. (D) GBM
2362 provides an example of prominent focal cytoplasmic detection. Normal CNS histology was also stained with 1708, and no IHC reactivity
was observed (results not shown).
Figure 5 Kaplan-Meier curve of time to progression stratified by MRP3 RNA transcript levels for newly diagnosed GBM patients. Low/
Moderate (n = 24): relative RNA expression levels less than or equal to 10-fold those of normal brain sample. High (n = 43): relative RNA
expression levels greater than 10-fold those of normal brain sample. 95% Confidence interval: 1.54, 4.80; p = 0.002.
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sible (cell surface or matrix)a tad e n s i t ys u f f i c i e n tf o r
targeting and significant cell kill. The criterion of abso-
lute tumor specificity is rarely met, and current
approaches often must target tumor-associated antigens
(ratio of neoplastic tissue to normal tissue expression
acceptable for lack of bystander effect).
In the present study, we have demonstrated that the
MRP3 gene is expressed both at the mRNA level and
the protein level in high-grade gliomas, but minimally in
normal brain tissue. By quantitative RT-PCR analysis of
67 newly diagnosed GBM patient samples for MRP3
mRNA expression, 88% of the samples were positive,
and 64% showed levels 10 times greater than the level
of MRP3 mRNA expression in normal brain. Immuno-
histochemical analysis of 46 cases revealed that 91% of
the GBM samples expressed MRP3 protein detectable
by immunohistochemistry. The predominant staining
pattern in all GBM was either parenchymal distribution
only (22/46, 48%) or mixed perivascular and parenchy-
mal in orientation, either focal or diffuse in distribution
(18/46, 39%), with few cases showing only prominent
perivascular distribution (2/46, 4%). As for the cellular
origin of MRP3 expression in the bulk tumors, five of
six GBM-derived cell lines examined in this study were
positive for MRP3 mRNA transcripts (Fig. 2), this result
supporting the view that MRP3 is produced mainly by
transformed cells in glioma tissues.
Our results and those of other researchers indicate
that MRP3 is highly expressed at gene and protein levels
in human glioma cell lines and in clinical glioma speci-
mens of grades III and IV [25]; consistent with other
studies, we observed no apparent expression of MRP3 in
normal brain tissue [45]. In addition, of the MRP family
genes, MRP1 was also found to have increased mRNA
expression in some human glioma cell lines and clinical
samples [24,25]. However, MRP1 is known to be
expressed in normal brain tissue [27]. MRP4 and MRP5
have been reported to exhibit expression in two glioblas-
toma cell lines, whereas MRP2 was not expressed in
malignant glioma cells [24,25]. Bronger et al. have also
detected the expression of other MRP family members,
such as MRP4 and MRP5, in the blood-brain barrier
and in the glioma cells at protein level [46]. Localization
of MRP1, MRP4, and MRP5 protein in rapidly frozen
perilesional samples of several regions of adult human
brain was reported by Nies et al. [47]. Among normal
vital organs outside the CNS, MRP3 protein expression
has been observed in adrenal gland, kidney, and tissues
associated with the circulation of bile acids [20].
However, the expression of MRP3 in normal tissues
outside the CNS will not compromise the compartmen-
tal delivery of MRP3-related immunological agents
within the CNS, because the optimal route for the
administration of MAb-based therapeutic agents for
tumors localized within the CNS is through surgically
created resection cavities or saturation of an entire
hemisphere by intracranial microdiffusion, called con-
vection-enhanced delivery, to the brain tumor [48],
which allows direct parenchymal infusion of therapeu-
tics, bypassing the blood-brain barrier. Only trace
amounts of therapeutics distribute systemically, and the
possibility of life-threatening side effects, such as lung
edema, would be minimal. However, these focal deliv-
eries have limitations: Passive microdiffusion happens to
only a very poor extent, given the gliosis reaction in the
wall of the surgical cavity, and convection-enhanced
delivery must take into account modern calculations for
isodose delivery distributions to cover the relevant areas
[49].
Localization to the tumor cell surface membrane or
extracellular matrix is another prerequisite for target
antigens in MAb-mediated therapy [50]. Amino acid
sequence analysis has shown that in a topological
model, MRP3 comprises seven domains, three of which
contain multiple extracellularly expressed regions, while
the remaining four are intracellularly located [40].
Although MRP3 protein is predicted to integrate in the
cell surface membrane, the precise membrane topology
of MRP3 is complex and remains unclear. Depending
upon the software used, 16-18 transmembrane domains
are predicted for MRP3, which complicates finding the
precise location of extracellular epitopes of MRP3 [40].
To address this, our immunization was performed with
fusion protein MAR3-MBP (MAR3; amino acids 984-
1224 of MRP3), which may contain extracellular epi-
topes of MRP3, and serum titer was monitored by the
reactivity with MRP3-expressing GBM cells under con-
ditions detecting cell surface reactivity only. The result-
ing rabbit antiserum 1708 and murine MAb 16A11,
derived from immunization with MAR3-MBP, recog-
nized cell-surface-expressed MRP3 as defined by immu-
nofluorescence analysis of MRP3-positive GBM cells
under non-fixed conditions. These results from flow
cytometry, along with IHC findings showing membra-
nous staining of tumor cells, indicate the expression of
MRP3 protein on the surface membrane of glioblastoma
cells in vitro and in vivo. Recently, we have isolated
scFvs M25 and M58, which specifically react with the
extracellular N-terminus of MRP3, for IHC evaluation
of human gliomas to determine the localization of
MRP3 antigen. These Fv-based recombinant antibodies,
possessing superior tumor penetration capabilities and
selectively targeting tumor cells that express MRP3, may
potentially be used in immunotherapy and diagnosis for
brain tumors and other cancers [51].
Other factors that define the targetability of antigen
molecules involve antigen density [52] and stability (lack
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ing to ligand or antibody) [50]. Results from immu-
notherapeutic experiments using xenograft models have
revealed that the extent of tumor reduction elicited by a
single MAb is generally proportional to the antigen den-
sity at the cell surface [52]. Although the minimum anti-
gen density required for successful MAb-mediated
therapy varies, depending on the mechanisms of action
of cytotoxic conjugates, the general consensus is that ≥1
×1 0
4 protein molecules per cell would be required for
biologically effective targeting [43]. Preliminary data
obtained by quantitative FACS analysis with MAb
16A11 directed against MAR3-MBP indicates that
human malignant glioma cell lines T98G, D247 MG,
and D54 MG express 0.3-4.9 × 10
5 MRP3 molecules per
cell. More significantly, biopsy-derived GBM cells from
22/27 patients expressed MRP3 at a density ranging
from 1.7 × 10
4 to 6.5 × 10
5 molecules per cell, well
within the density range required for targeting.
The molecular mechanisms underlying overexpression
of the MRP3 gene in gliomas remain to be determined.
Activation of the MRP family genes can be achieved in
several ways. For MRP1, an increase in MRP1 mRNA in
cultured cell lines that have been selected for in vitro
drug resistance is frequently associated with amplifica-
tion of its cognate gene and at least some level of rear-
rangement [53], while elevated MRP1 mRNA found in
human tumor samples occurs without [54] or only
rarely with gene amplification [55]. Thus, further inves-
tigation could determine whether MRP3 mRNA overex-
pression in human gliomas also is associated with an
increase of gene copy number. Up-regulation of MRP3
mRNA can occur by mechanisms other than gene
amplification. Sequence analysis of the 5′-flanking region
of the MRP3 gene has revealed that the MRP3 promoter
lacks the typical TATA box and contains multiple
potential binding sites for a number of transcription fac-
tors, including AP1, AP2, N-MYC, Sp1, and PEA-3
[41,56]. Alternatively, methylation of the promoter
region, the stability of mRNA, or translational efficiency
may be altered, which can contribute to the hyperex-
pression of MRP3.
The biological significance of aberrant expression of
MRP3 in glioma tissues is not yet known. Our results
and reports from other researchers [24,25] have demon-
strated that MRP3 mRNA levels increase with tumor
grade, indicating that MRP3 is likely to be a potential
progression marker of glial tumors. In human colorectal
carcinoma cell lines, the enhanced expression of MRP3
mRNA is associated with the inactivation of the p53
gene [57]. MRP3 gene expression may be regulated at
the genetic level, depending on the status of oncogenes
and/or tumor suppressor genes involved in the tumori-
genesis of gliomas. On the other hand, one of the
outstanding features of MRP3 is its inducibility by exter-
nal stimuli, such as chemical carcinogens and anticancer
drugs. This inducible nature of MRP3 has been observed
in primate and rodent tissues and in a variety of cul-
tured cells [58,59], and drug-induced MRP3 may pro-
vide an important mechanism for cytoprotection from
the toxicity of xenobiotics. However, glioma cases exam-
ined in this study exhibited MRP3 overexpression prior
to the exposure to antineoplastic reagents. MRP3 can
also be up-regulated in response to a change in the
intracellular redox state [57] and, as postulated for
MRP1 [60], may improve cellular defense status against
oxidative metabolites that accumulate during tumor
growth.
The categorical variables of age, mRNA transcript
level, and IHC staining intensity were used to construct
Kaplan-Meier curves, and our univariate analysis
demonstrated efficacy in predicting survival in the newly
diagnosed GBM population. The univariate analyses
show that patients with high MRP3 mRNA expression
level had a higher risk (2.71 times higher) of death than
the patients with low/moderate MRP3 mRNA expres-
sion level. The results of survival analysis suggest that
the relative MRP3 mRNA levels represent a potential
prognostic predictor of poor GBM patient survival.
There are only a few molecular markers that are prog-
nostic for survival in malignant gliomas. Elevated
expression of MRP3 in GBM patient specimens, strong
GST-π protein expression in human gliomas [61], a
functional polymorphism in EGF [62], and high
GPNMB expression in GBM patients [9] are associated
with clinically more aggressive gliomas and are useful
and powerful prognostic markers of poor patient
survival.
Conclusions
In conclusion, human GBMs overexpress MRP3 at both
mRNA and protein levels, and elevated MRP3 mRNA
levels in GBM biopsy samples correlated with a higher
risk of death. These data indicate that the tumor-asso-
ciated antigen MRP3 has potential use as a prognostic
predictor for malignant gliomas. We further demon-
strate that immunotherapeutic strategies designed to
target MRP3 may be successful for treating malignant
glioma patients.
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